Porownywarka

Thyreogen vs Livagen side-by-side

Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.

Wybrane (2/4)

ThyreogenLivagen

Udostępnij porównanie peptydów

Wlasciwosc	Thyreogen	Livagen
Kategoria	Bioregulatory	Bioregulatory
Znany tez jako	-	Lys-Glu-Asp-Ala, KEDA
Zatwierdzony przez FDA	Nie	Nie
Status kliniczny	Preclinical research; approved in Russia as a supplement Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA	Preclinical research; reported as approved in Russia as a supplement Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA
Czego oczekiwac	Thyroid function, metabolism, thyroid health	Gene expression, cellular aging, liver health
Jak dziala	Thyreogen is described under the Khavinson bioregulator framework. In that model, short tissue-derived peptides are hypothesized to enter cells and influence gene-expression programs, potentially through DNA-associated effects. The source reports thyroid-focused vendor claims involving thyroid-cell metabolism and T3, T4, and calcitonin output, but it also states that a Thyreogen-specific receptor, pathway, or independently established mechanism has not been mapped.	Livagen is presented as a short peptide bioregulator with a proposed epigenetic mode of action. The supplied source describes in vitro findings in which KEDA was associated with less condensed pericentromeric heterochromatin and increased ribosomal gene activity in cells from older donors. This remains a hypothesis based on cell-level work; the source does not establish how a tetrapeptide would produce selective nuclear effects in humans.
Typowe dawkowanie	10-20 mg daily · Once or twice daily	10-20 mg daily · Once or twice daily · 10-30 day cycles · Oral capsules or sublingual
Dawkowanie z badań	10-20 mg daily · 10-30 day cycles · Oral capsules or sublingual	10-20 mg daily · 10-30 day cycles · Oral capsules or sublingual
Typowy czas trwania	10-30 day cycles	10-30 day cycles
Podanie	Oral capsules or sublingual	Oral capsules or sublingual
Timing	Morning on an empty stomach Take on an empty stomach	Morning on an empty stomach Take on an empty stomach
Poziom dowodów	Przedkliniczne	Przedkliniczne
Mozliwe skutki uboczne	Generally well tolerated (Reported by the source; detailed safety data are limited.) May affect thyroid hormone levels (Source-reported safety consideration.) Limited safety data outside Russia (Evidence base may not generalize broadly.) +1 więcej Not FDA approved (Regulatory status note, not a physiological side effect.)	Generally reported as well tolerated (Source-reported safety characterization; detailed adverse event data are not provided.) Limited safety data outside Russia (Safety evidence is described as geographically and evidentially limited.) Not FDA approved (This is regulatory status, not an adverse effect.)
Podsumowanie researchu	The source places Thyreogen within the broader Khavinson peptide bioregulator literature, which includes Russian publications and review-level discussions of short peptides as possible epigenetic regulators. It also states that evidence directly testing Thyreogen as a specific product is sparse, with no registered randomized placebo-controlled human trials for thyroid disease identified in the source material. Reported animal or family-level endocrine and geroprotective findings should therefore be treated as hypothesis-generating rather than proof for Thyreogen itself.	The supplied research description centers on a narrow body of mechanistic work attributed mainly to Khavinson, Lezhava, and collaborators. It highlights a 2002 Bulletin of Experimental Biology and Medicine report in which cultured lymphocytes from older donors were exposed to Livagen and assessed for ribosomal gene activity and heterochromatin structure. Related peptide bioregulators were reported in the same research line. The evidence described is cell-level and mechanistic rather than clinical, and the source states that randomized human trials for Livagen were not identified.
Referencje	PubMed PubMed Central +1 więcej SpringerLink	Źródło Źródło +2 więcej Źródło Źródło
Pełny profil	Zobacz szczegóły	Zobacz szczegóły

Zapisz to porównanie

Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.

Zapisz porównanie - darmowe konto

Trackuj swoja ścieżkę peptydówa

Zamien research w prywatny log protokołu, gdy będziesz gotowy.

Trackuj ścieżkę peptydówa

Wyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.

Wlasciwosc

Thyreogen

Livagen

Kategoria

Bioregulatory

Znany tez jako

Lys-Glu-Asp-Ala, KEDA

Zatwierdzony przez FDA

Nie

Status kliniczny

Preclinical research; approved in Russia as a supplement

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Preclinical research; reported as approved in Russia as a supplement

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Czego oczekiwac

Thyroid function, metabolism, thyroid health

Gene expression, cellular aging, liver health

Jak dziala

Thyreogen is described under the Khavinson bioregulator framework. In that model, short tissue-derived peptides are hypothesized to enter cells and influence gene-expression programs, potentially through DNA-associated effects. The source reports thyroid-focused vendor claims involving thyroid-cell metabolism and T3, T4, and calcitonin output, but it also states that a Thyreogen-specific receptor, pathway, or independently established mechanism has not been mapped.

Livagen is presented as a short peptide bioregulator with a proposed epigenetic mode of action. The supplied source describes in vitro findings in which KEDA was associated with less condensed pericentromeric heterochromatin and increased ribosomal gene activity in cells from older donors. This remains a hypothesis based on cell-level work; the source does not establish how a tetrapeptide would produce selective nuclear effects in humans.

Typowe dawkowanie

10-20 mg daily · Once or twice daily

10-20 mg daily · Once or twice daily · 10-30 day cycles · Oral capsules or sublingual

Dawkowanie z badań

10-20 mg daily · 10-30 day cycles · Oral capsules or sublingual

Typowy czas trwania

10-30 day cycles

Podanie

Oral capsules or sublingual

Timing

Morning on an empty stomach

Take on an empty stomach

Morning on an empty stomach

Take on an empty stomach

Poziom dowodów

Przedkliniczne

Mozliwe skutki uboczne

Generally well tolerated (Reported by the source; detailed safety data are limited.)
May affect thyroid hormone levels (Source-reported safety consideration.)
Limited safety data outside Russia (Evidence base may not generalize broadly.)

+1 więcej

Not FDA approved (Regulatory status note, not a physiological side effect.)

Generally reported as well tolerated (Source-reported safety characterization; detailed adverse event data are not provided.)
Limited safety data outside Russia (Safety evidence is described as geographically and evidentially limited.)
Not FDA approved (This is regulatory status, not an adverse effect.)

Podsumowanie researchu

The source places Thyreogen within the broader Khavinson peptide bioregulator literature, which includes Russian publications and review-level discussions of short peptides as possible epigenetic regulators. It also states that evidence directly testing Thyreogen as a specific product is sparse, with no registered randomized placebo-controlled human trials for thyroid disease identified in the source material. Reported animal or family-level endocrine and geroprotective findings should therefore be treated as hypothesis-generating rather than proof for Thyreogen itself.

The supplied research description centers on a narrow body of mechanistic work attributed mainly to Khavinson, Lezhava, and collaborators. It highlights a 2002 Bulletin of Experimental Biology and Medicine report in which cultured lymphocytes from older donors were exposed to Livagen and assessed for ribosomal gene activity and heterochromatin structure. Related peptide bioregulators were reported in the same research line. The evidence described is cell-level and mechanistic rather than clinical, and the source states that randomized human trials for Livagen were not identified.

Referencje

PubMed PubMed Central

+1 więcej

+2 więcej

Pełny profil